Table 5.
Certainty of evidence quality.
| Author, year | Outcomes | Limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Relative effect (95% CI) | Quality |
|---|---|---|---|---|---|---|---|---|
| Tang et al. [14], 2021 | Effective rate | -1 | 0 | 0 | 0 | 0 | OR 3.77 (2.61, 5.45) | M |
| Adverse events | -1 | 0 | 0 | 0 | 0 | OR 0.43 (0.21, 0.90) | M | |
| Recurrence rate | -1 | 0 | 0 | -1 | 0 | OR 0.16 (0.05, 0.50) | L | |
|
| ||||||||
| Xing [15], 2021 | Level of TNF-α | -1 | 0 | 0 | -1 | -1 | SMD -0.81 (-1.07, -0.54) | CL |
| Level of IL-6 | -1 | -1 | 0 | -1 | -1 | SMD -1.20 (-2.00, -0.41) | CL | |
|
| ||||||||
| Qin et al. [16], 2019 | Effective rate | -1 | 0 | 0 | 0 | 0 | RR 1.18 (1.06, 1.30) | M |
| Adverse events | -1 | 0 | 0 | -1 | 0 | RR O.11 (0.041, 1.92) | L | |
| Mucosal improvement | -1 | 0 | 0 | -1 | 0 | RR 1.13 (0.95, 1.88) | L | |
|
| ||||||||
| Fan [17], 2019 | Effective rate | -1 | 0 | 0 | 0 | 0 | RR 1.21 (1.16, 1.27) | M |
| Recurrence rate | -1 | 0 | 0 | -1 | 0 | RR 0.18 (0.06, 0.61) | L | |
| Adverse events | -1 | 0 | 0 | 0 | 0 | RR 0.37 (0.15, 0.90) | M | |
| UCEIS score | -1 | -1 | 0 | 0 | 0 | MD -0.63 (-1.26, -0.01) | L | |